# Creative Medical Technology Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2017

- Company: [Creative Medical Technology Holdings, Inc.](/companies/celz.md) (CIK 1187953)
- Form: 10-Q
- Filed: 2017-08-14
- Accepted by EDGAR: Aug 14, 2017, 12:19 ET
- Period: 2017-06-30
- Accession: 0001144204-17-042898
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1187953/000114420417042898/v472848_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1187953/000114420417042898/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2017-04-01 to 2017-06-30 | $0 | us-gaap:Revenues |
| Revenue | 6 months, 2017-01-01 to 2017-06-30 | $0 | us-gaap:Revenues |
| Research and development | 3 months, 2017-04-01 to 2017-06-30 | $25.2k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2017-01-01 to 2017-06-30 | $85.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2017-04-01 to 2017-06-30 | −$886.4k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2017-01-01 to 2017-06-30 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-04-01 to 2017-06-30 | $63.2k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2017-01-01 to 2017-06-30 | $65.7k | us-gaap:InterestExpense |
| Net income | 3 months, 2017-04-01 to 2017-06-30 | −$886.4k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2017-01-01 to 2017-06-30 | −$1.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-04-01 to 2017-06-30 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2017-01-01 to 2017-06-30 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Cash and equivalents | at 2017-06-30 | $104.4k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-06-30 | $104.4k | us-gaap:AssetsCurrent |
| Total assets | at 2017-06-30 | $299.6k | us-gaap:Assets |
| Current liabilities | at 2017-06-30 | $1.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-06-30 | $1.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2017-06-30 | −$1.0m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Management's discussion and analysis

As filed, 14,937 characters.

*Management’s Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets and statements of income. This section should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2016, and our interim financial statements and accompanying notes to these financial statements included in this report. All amounts are in U.S. dollars.*

### Forward-Looking Statement Notice

This quarterly report on Form 10-Q contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, those set forth in our most recent annual report referenced below.

This report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements.

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

### Overview

On May 18, 2016, Creative Medical Technology Holdings, Inc., formerly known as Jolley Marketing, Inc., a Nevada corporation (the “**Company”, “we”, “our”**, or “**us”**), closed (the “**Closing”**) the Agreement and Plan of Merger (the “**Merger Agreement”**) with Creative Medical Technologies, Inc., a Nevada corporation (“**CMT”**), Steven L. White, the principal shareholder and the sole officer and director of the Company (“**Mr. White”**), and Jolley Acquisition Corp., a Nevada corporation and wholly owned subsidiary of the Company (the “**Merger Sub”**). As a result of the Closing of the Merger Agreement, the Merger Sub was merged with and into CMT with CMT being the surviving corporation and CMT became a wholly-owned subsidiary of the Company. Upon completion of the transaction, we acquired CMT (which is now our wholly-owned subsidiary) and became a company engaged in stem cell research and applications for use to treat multiple unmet medical needs. CMT was incorporated in the State of Nevada on December 30, 2015. All references to the Company after the Closing refer to Creative Medical Technology Holdings, Inc. and Creative Medical Technologies, Inc., collectively.

We are considered to be a clinical stage company, since we are devoting substantially all of our efforts to establishing our business and because our planned principal operations have not commenced. Our fiscal year end is December 31st . We have acquired the licensing rights for a novel, embryonic fluid-based stem cell, purchased the patents for our ED and male infertility treatments, filed patent applications for stroke, recurrent miscarriages, and female sexual dysfunction, are performing a clinical trial to validate the safety and efficacy of our ED treatment and are performing pre-clinical research on our embryonic fluid-based stem cell in the laboratory.

Funds for our operations have been provided by our parent company, Creative Medical Health, Inc. (“**CMH”**) and outside investors. In February 2016 and September 2016, CMH purchased shares of our common stock for cash consideration of $49,500 and $30,000, respectively. In addition, CMH has loaned operating funds to CMT in the form of lines of credit evidenced by promissory notes. As of June 30, 2017, total amounts received from CMT in connection with three promissory notes is $125,000. Each promissory note representing the loans bears interest at 8% per annum from the date funds were received. The first promissory note is dated February 2, 2016, and principal and interest under the note are due on or before April 30, 2018. This promissory note is fully funded in the principal amount of $50,000. The second promissory note is dated May 1, 2016, and principal and interest under the note is due on or before July 31, 2017. In addition, CMH loaned $25,000 to CMT to pay a portion of the approximately $45,000 in outstanding payables of the Company at closing of the reverse merger on May 18, 2016. The loan is evidenced by a promissory note dated May 18, 2016, which bears interest at 8% and which matures on May 18, 2018. From August 2016 through March 2017, we sold 6,000,000 shares of common stock for gross proceeds of $600,000, and issued at no additional cost, three-year warrants to purchase 600,000 shares at $0.10 per share. Of the total sales, $30,000 was received from Creative Medical Health.

As of June 30, 2017, we have accrued interest of $7,387 arising from the related party notes of $125,000.

### Plan of Operations

We anticipate that if our clinical studies on our ED stem cell treatment are successful, we can commence marketing kits for the treatment in 2018. For the next 12 months our plan of operations is to complete these clinical trials and commence marketing of the kits. We estimate the costs to complete the clinical trials will be approximately $600,000, excluding overhead and other costs associated with maintaining our company structure. We believe that our current cash on hand would meet our cash flow requirements for only a few more months. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.

### Results of Operations – For the Three Month Period Ended June 30, 2017 and 2016

***Gross Revenue.*** We generated no gross revenue for the three month period ended June 30, 2017 and June 30, 2016.

***General and Administrative Expenses.*** General and administrative expenses for the three month period ended June 30, 2017, totaled $368,016, in comparison with $187,576, for the comparable quarter a year ago. The increase of $180,440, or 96% is primarily due to $140,957 in stock-based compensation combined with legal and accounting fees associated with debt issuances and public company reporting.

***Research and Development Expenses.*** Research and development expenses for the three month period ended June 30, 2017, totaled $25,189 in comparison with $18,028, for the comparable quarter a year ago. The increase of $7,161, or 40% is primarily due to an increase of $5,600 in laboratory expenses associated with pre-clinical research on the Amniostem™ stem cell.

***Other Income / Expense.*** Other expenses for the three month period ended June 30, 2017, totaled $490,365 in comparison with $1,150, for the comparable quarter a year ago. The increase of $489,215, or 42,540% is due to an increase of $62,090 in interest expense and $427,124 in expense associated with the change in the fair value of derivative liabilities.

***Net Loss.*** For the reasons stated above, our net loss for the three month period ended June 30, 2017 totaled $886,356 in comparison to $209,247, for the comparable quarter a year ago.

### Results of Operations – For the Six Month Period Ended June 30, 2017 and 2016

***Gross Revenue.*** We generated no gross revenue for the six month period ended June 30, 2017 and June 30, 2016.

***General and Administrative Expenses.*** General and administrative expenses for the six month period ended June 30, 2017, totaled $546,394, in comparison with $328,752, for the comparable six month period a year ago. The increase of $217,642, or 66% is primarily due to $142,423 in stock-based compensation combined with legal and accounting fees associated with debt issuances and public company reporting.

***Research and Development Expenses.*** Research and development expenses for the six month period ended June 30, 2017, totaled $85,020 in comparison with $22,392, for the comparable six month period a year ago. The increase of $62,628, or 280% is primarily due to an increase of $38,724 in clinical research expenses on the ED stem cell trial and an increase of $18,311 in laboratory expenses associated with pre-clinical research on the Amniostem™ stem cell.

***Other Income / Expense.*** Other expenses for the six month period ended June 30, 2017, totaled $492,870 in comparison with $1,866, for the comparable six month period a year ago. The increase of $491,004, or 26,313% is due to an increase of $63,879 in interest expense and $427,124 in expense associated with the change in the fair value of derivative liabilities.

***Net Loss.*** For the reasons stated above, our net loss for the six month period ended June 30, 2017 totaled $1,129,707 in comparison to $357,092, for the comparable six month period a year ago.

### Liquidity and Capital Resources

As of June 30, 2017, our principal source of liquidity was a combination of $600,000 raised through the sale of the Company’s common stock, the initial capital contribution of $49,500 paid by CMH for founder’s shares of CMT, $125,000 borrowed under promissory notes from CMH and $420,000 borrowed under promissory notes and debentures from third-party lenders for which was used to pay operating expenses and to satisfy CMTH payables as of the closing of the reverse merger with CMT. Going forward, our short-term funding needs are expected to be satisfied by funds to be loaned to us by various financiers. Our long-term liquidity needs are expected to be satisfied through offerings of our equity securities. We do not have any arrangements, agreements, or sources for long-term funding.

Our commitments for expenditures relate to short-term notes coming due over the next 12 months, the completion of the clinical studies for the ED stem cell treatment and general and administrative costs, including reimbursements to our parent company for services performed by their executive officers on our behalf. During the next 12 months we also anticipate commencing marketing activities for our ED treatment in conjunction with the anticipated completion of the clinical trials.

### Cash Flows

***Net Cash used in Operating Activities.*** We used cash in our operating activities due to our losses from operations. Net cash used in operating activities was $493,222 for the six month period ended June 30, 2017 in comparison to $138,955 for the comparable period a year ago, an increase of $354,267 or 255%. The increase in cash used in operations was primarily related to payments towards an outstanding balance of management fees payable to a related party, increases in research expenses, increased capital markets marketing costs and increased legal and accounting fees associated with public company reporting and audit requirements.

***Net Cash used in Investing Activities.*** In the six month period ended June 30, 2017 we used $100,000 to purchase the StemSpine patent. There was no cash used in investing activities for the comparable period a year ago.

***Net Cash From Financing Activities.*** In the six month period ended June 30, 2017 we raised $100,000 through the sale of common stock and $375,750 through the issuance of convertible and non-convertible debt. In the six month period ended June 30, 2016, we raised $118,931 through the issuance of debt. The increase in cash flows from financing activities was primarily related to our need to obtain additional capital due to the payments towards an outstanding balance of management fees payable to a related party, increases in research expenses, increased capital markets marketing costs and increased legal and accounting fees associated with public company reporting and audit requirements.

### Basis of Presentation / Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2017, the Company had $104,396 of available cash and a working capital deficit of 1,209,524. For the six month period ended June 30, 2017, the Company had no revenue, no operating income and used net cash for operating activities of $493,222. These factors, among others, indicate that the Company may be unable to continue as a going concern for the next twelve months. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing as may be required, and ultimately to attain sufficient cash flow from operations to meet its obligations on a timely basis. Management is in the process of negotiating various financing plans including access to ongoing credit facilities and possible sale of capital stock either in private of in public offerings and believes these steps may generate sufficient cash flow for the Company to continue as a going concern. If the Company is unsuccessful in these efforts, it may be required to substantially curtail or terminate its operations.

### Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity capital expenditures or capital resources.

## Controls and procedures

As filed, 3,234 characters.

### Evaluation of disclosure controls and procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 15(d)-15(e) of the Securities Exchange Act of 1934, as amended (the “**Exchange Act”**)) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Previously, the Company had a material weaknesses which was first identified by the Company’s management and independent accountants during the quarter ended June 30, 2016. The material weakness was related to the initial treatment of the reverse merger (recapitalization) which was initially reported as of the date the initial stock of the Company was issued, rather than as of the origination date of the Company and therefore the restatement (arising from the reverse merger) of the equity section was required to be changed from January 2016 to December 30, 2015. In addition, a second weakness was noted in the original disclosure of our financial information provided to our independent accountants, wherein the recording date of the patent acquired from a related party was not updated to recognize the change in the terms of the acquisition arising from the reverse merger. Although these errors were addressed and corrected within the June 30, 2016 10-Q, as of December 31, 2016, the material weakness related to the Company not having the ability to provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements and related disclosures in accordance with U.S. generally accepted accounting principles still remains.

To address these material weaknesses, in 2016 we engaged a third party that specializes in technical accounting and financial reporting to assist us in preparation of our quarterly and annual financial statements and to assist us in documenting our internal controls. During the six month period ended June 30, 2017, we determined that these material weaknesses had been remediated and thus no longer exist. We are not aware of significant weaknesses in addition to the items noted above.

### Changes in internal control over financial reporting

Other than disclosed above, there were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed Aug 14, 2017.
Source: SEC EDGAR, the filing index for accession 0001144204-17-042898. Last ingested by Listed: Nov 14, 2026, 19:08 ET. No prices; not investment advice.
